Arjun Balar

Arjun Balar

Company: Loxo Oncology

Job title: Vice President - Global Clinical Development


Revealing Program Updates from LY3537982, a Highly Selective & Potent KRAS G12C Inhibitor 9:30 am

Discussing the discovery and rational design of LY3537982 its transition from bench to clinic Reviewing recent first-in-human data for LY3537982 in patients with KRAS G12C-Mutant Advanced Solid Tumors, Including NSCLC and CRC Exploring LY3537982 development avenues and promising future directionsRead more

day: Conference Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.